TW201215389A - Sustained-release therapeutic agent for hypertension and renal dysfunction - Google Patents

Sustained-release therapeutic agent for hypertension and renal dysfunction Download PDF

Info

Publication number: TW201215389A
Authority: TW; Taiwan
Prior art keywords: hypertension; renal dysfunction; group; normal high; blood pressure
Prior art date: 2010-06-25

Application number

TW100122222A

Other languages

English (en)

Chinese (zh)

Inventor

Takashi Shirakura

Mizuho Tamura

Yoshimasa Takahashi

Ippei Kuwahara

Original Assignee

Teijin Pharma Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-06-25

Filing date

2011-06-24

Publication date

2012-04-16

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45371556&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW201215389(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-06-24 Application filed by Teijin Pharma Ltd filed Critical Teijin Pharma Ltd

2012-04-16 Publication of TW201215389A publication Critical patent/TW201215389A/zh

Links

206010020772 Hypertension Diseases 0.000 title claims abstract description 65
230000008085 renal dysfunction Effects 0.000 title claims abstract description 41
238000013268 sustained release Methods 0.000 title claims abstract description 35
239000012730 sustained-release form Substances 0.000 title claims abstract description 35
239000003814 drug Substances 0.000 title claims abstract description 8
229940124597 therapeutic agent Drugs 0.000 title 1
-1 2-phenylthiazole compound Chemical class 0.000 claims abstract description 22
150000003839 salts Chemical class 0.000 claims abstract description 18
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
239000000126 substance Substances 0.000 claims abstract description 11
239000004480 active ingredient Substances 0.000 claims abstract description 10
230000003449 preventive effect Effects 0.000 claims abstract description 4
238000000034 method Methods 0.000 claims description 29
201000001431 Hyperuricemia Diseases 0.000 claims description 16
206010036790 Productive cough Diseases 0.000 claims description 15
208000024794 sputum Diseases 0.000 claims description 15
210000003802 sputum Anatomy 0.000 claims description 15
230000002265 prevention Effects 0.000 claims description 12
201000005569 Gout Diseases 0.000 claims description 10
230000036772 blood pressure Effects 0.000 claims description 9
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
125000000217 alkyl group Chemical group 0.000 claims description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
125000004093 cyano group Chemical group *C#N 0.000 claims description 4
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 4
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
125000003386 piperidinyl group Chemical group 0.000 claims description 4
208000007342 Diabetic Nephropathies Diseases 0.000 claims description 3
206010018364 Glomerulonephritis Diseases 0.000 claims description 3
208000010159 IgA glomerulonephritis Diseases 0.000 claims description 3
206010021263 IgA nephropathy Diseases 0.000 claims description 3
125000003545 alkoxy group Chemical group 0.000 claims description 3
230000001684 chronic effect Effects 0.000 claims description 3
208000033679 diabetic kidney disease Diseases 0.000 claims description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 3
230000003907 kidney function Effects 0.000 claims description 3
125000002757 morpholinyl group Chemical group 0.000 claims description 3
238000002560 therapeutic procedure Methods 0.000 claims description 3
125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 2
208000011580 syndromic disease Diseases 0.000 claims 2
ZGWGSEUMABQEMD-UHFFFAOYSA-N 4-methyl-1,3-thiazole-5-carboxylic acid Chemical compound CC=1N=CSC=1C(O)=O ZGWGSEUMABQEMD-UHFFFAOYSA-N 0.000 claims 1
208000035475 disorder Diseases 0.000 claims 1
239000003795 chemical substances by application Substances 0.000 abstract description 12
229940079593 drug Drugs 0.000 abstract description 6
230000001225 therapeutic effect Effects 0.000 abstract description 5
BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 description 20
229960005101 febuxostat Drugs 0.000 description 19
210000004369 blood Anatomy 0.000 description 12
239000008280 blood Substances 0.000 description 12
238000002360 preparation method Methods 0.000 description 12
108010088751 Albumins Proteins 0.000 description 10
102000009027 Albumins Human genes 0.000 description 10
239000012729 immediate-release (IR) formulation Substances 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 8
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
230000000694 effects Effects 0.000 description 8
230000002485 urinary effect Effects 0.000 description 8
210000002700 urine Anatomy 0.000 description 8
235000020188 drinking water Nutrition 0.000 description 6
239000003651 drinking water Substances 0.000 description 6
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 6
LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 5
TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 5
230000029142 excretion Effects 0.000 description 5
229940116269 uric acid Drugs 0.000 description 5
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 4
229940123769 Xanthine oxidase inhibitor Drugs 0.000 description 4
239000000654 additive Substances 0.000 description 4
229920002678 cellulose Polymers 0.000 description 4
239000001913 cellulose Substances 0.000 description 4
229940109239 creatinine Drugs 0.000 description 4
239000003405 delayed action preparation Substances 0.000 description 4
239000000203 mixture Substances 0.000 description 4
230000035488 systolic blood pressure Effects 0.000 description 4
229940126585 therapeutic drug Drugs 0.000 description 4
239000003064 xanthine oxidase inhibitor Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
239000002253 acid Substances 0.000 description 3
230000000996 additive effect Effects 0.000 description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000001768 carboxy methyl cellulose Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
238000009472 formulation Methods 0.000 description 3
208000017169 kidney disease Diseases 0.000 description 3
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
239000001301 oxygen Substances 0.000 description 3
229910052760 oxygen Inorganic materials 0.000 description 3
230000000069 prophylactic effect Effects 0.000 description 3
235000018102 proteins Nutrition 0.000 description 3
102000004169 proteins and genes Human genes 0.000 description 3
108090000623 proteins and genes Proteins 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
239000008399 tap water Substances 0.000 description 3
235000020679 tap water Nutrition 0.000 description 3
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
108060006698 EGF receptor Proteins 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
239000001856 Ethyl cellulose Substances 0.000 description 2
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
238000009530 blood pressure measurement Methods 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
235000015165 citric acid Nutrition 0.000 description 2
229960004106 citric acid Drugs 0.000 description 2
CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 description 2
PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
230000035487 diastolic blood pressure Effects 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
201000010099 disease Diseases 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
235000019325 ethyl cellulose Nutrition 0.000 description 2
229920001249 ethyl cellulose Polymers 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000008103 glucose Substances 0.000 description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
239000000523 sample Substances 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011734 sodium Substances 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
239000000243 solution Substances 0.000 description 2
238000011699 spontaneously hypertensive rat Methods 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
229920003169 water-soluble polymer Polymers 0.000 description 2
XUCIJNAGGSZNQT-JHSLDZJXSA-N (R)-amygdalin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O[C@@H](C#N)C=2C=CC=CC=2)O1 XUCIJNAGGSZNQT-JHSLDZJXSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
QIJIUJYANDSEKG-UHFFFAOYSA-N 2,4,4-trimethylpentan-2-amine Chemical compound CC(C)(C)CC(C)(C)N QIJIUJYANDSEKG-UHFFFAOYSA-N 0.000 description 1
BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
WYKHSBAVLOPISI-UHFFFAOYSA-N 2-phenyl-1,3-thiazole Chemical compound C1=CSC(C=2C=CC=CC=2)=N1 WYKHSBAVLOPISI-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
ZUGAOYSWHHGDJY-UHFFFAOYSA-K 5-hydroxy-2,8,9-trioxa-1-aluminabicyclo[3.3.2]decane-3,7,10-trione Chemical compound [Al+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZUGAOYSWHHGDJY-UHFFFAOYSA-K 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
206010023126 Jaundice Diseases 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
239000002211 L-ascorbic acid Substances 0.000 description 1
235000000069 L-ascorbic acid Nutrition 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
PHENDEBCVTZAAB-UHFFFAOYSA-N O=C1CC(=CC=C1OCC(C)C)C=1SC(=C(N1)C)C(=O)O Chemical compound O=C1CC(=CC=C1OCC(C)C)C=1SC(=C(N1)C)C(=O)O PHENDEBCVTZAAB-UHFFFAOYSA-N 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
229940087098 Oxidase inhibitor Drugs 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
241000700159 Rattus Species 0.000 description 1
206010062237 Renal impairment Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
108010093894 Xanthine oxidase Proteins 0.000 description 1
102100033220 Xanthine oxidase Human genes 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
235000011054 acetic acid Nutrition 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
229940009456 adriamycin Drugs 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
LEWCAQWVBYTPMP-UHFFFAOYSA-K aluminum;magnesium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Mg+2].[Al+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O LEWCAQWVBYTPMP-UHFFFAOYSA-K 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
229940089837 amygdalin Drugs 0.000 description 1
YZLOSXFCSIDECK-UHFFFAOYSA-N amygdalin Natural products OCC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC(C#N)c3ccccc3 YZLOSXFCSIDECK-UHFFFAOYSA-N 0.000 description 1
229960004543 anhydrous citric acid Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
229960005070 ascorbic acid Drugs 0.000 description 1
235000003704 aspartic acid Nutrition 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
229920002988 biodegradable polymer Polymers 0.000 description 1
239000004621 biodegradable polymer Substances 0.000 description 1
230000004531 blood pressure lowering effect Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000004040 coloring Methods 0.000 description 1
230000008602 contraction Effects 0.000 description 1
239000007771 core particle Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
229960003624 creatine Drugs 0.000 description 1
239000006046 creatine Substances 0.000 description 1
229960001681 croscarmellose sodium Drugs 0.000 description 1
235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229960004679 doxorubicin Drugs 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
YGHHWSRCTPQFFC-UHFFFAOYSA-N eucalyptosin A Natural products OC1C(O)C(O)C(CO)OC1OC1C(OC(C#N)C=2C=CC=CC=2)OC(CO)C(O)C1O YGHHWSRCTPQFFC-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
230000006870 function Effects 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
238000009499 grossing Methods 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
150000002505 iron Chemical class 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
230000005977 kidney dysfunction Effects 0.000 description 1
239000004310 lactic acid Substances 0.000 description 1
235000014655 lactic acid Nutrition 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
229940117841 methacrylic acid copolymer Drugs 0.000 description 1
229920003145 methacrylic acid copolymer Polymers 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
IZXGZAJMDLJLMF-UHFFFAOYSA-N methylaminomethanol Chemical compound CNCO IZXGZAJMDLJLMF-UHFFFAOYSA-N 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
NOUUUQMKVOUUNR-UHFFFAOYSA-N n,n'-diphenylethane-1,2-diamine Chemical compound C=1C=CC=CC=1NCCNC1=CC=CC=C1 NOUUUQMKVOUUNR-UHFFFAOYSA-N 0.000 description 1
229940037525 nasal preparations Drugs 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
150000002923 oximes Chemical class 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
235000019271 petrolatum Nutrition 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
239000004626 polylactic acid Substances 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229920006316 polyvinylpyrrolidine Polymers 0.000 description 1
231100000857 poor renal function Toxicity 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000004393 prognosis Methods 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
201000001474 proteinuria Diseases 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
239000002994 raw material Substances 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
239000003871 white petrolatum Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

TW100122222A 2010-06-25 2011-06-24 Sustained-release therapeutic agent for hypertension and renal dysfunction TW201215389A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2010145056		2010-06-25

Publications (1)

Publication Number	Publication Date
TW201215389A true TW201215389A (en)	2012-04-16

Family

ID=45371556

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW100122222A TW201215389A (en)	2010-06-25	2011-06-24	Sustained-release therapeutic agent for hypertension and renal dysfunction

Country Status (26)

Country	Link
US (1)	US20130109726A1 (es)
EP (1)	EP2586442A4 (es)
JP (1)	JPWO2011162390A1 (es)
KR (1)	KR20130088755A (es)
CN (1)	CN102958521A (es)
AR (1)	AR082022A1 (es)
AU (1)	AU2011270133B2 (es)
BR (1)	BR112012032543A2 (es)
CA (1)	CA2803163A1 (es)
CL (1)	CL2012003661A1 (es)
CO (1)	CO6660504A2 (es)
EC (1)	ECSP12012352A (es)
MA (1)	MA34328B1 (es)
MX (1)	MX2012015040A (es)
MY (1)	MY160963A (es)
NZ (1)	NZ605516A (es)
PE (1)	PE20130241A1 (es)
PH (1)	PH12012502487A1 (es)
RU (1)	RU2013103366A (es)
SG (1)	SG186798A1 (es)
TN (1)	TN2012000568A1 (es)
TW (1)	TW201215389A (es)
UA (1)	UA107716C2 (es)
UY (1)	UY33468A (es)
WO (1)	WO2011162390A1 (es)
ZA (1)	ZA201209388B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PE20170306A1 (es)	2010-06-16	2017-05-06	Takeda Pharmaceuticals Usa Inc	Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
AU2011299153B2 (en)	2010-09-10	2014-10-30	Takeda Pharmaceuticals U.S.A., Inc.	Methods for concomitant treatment of theophylline and febuxostat
RU2014134845A (ru) *	2012-01-27	2016-03-20	Тейдзин Фарма Лимитед	Терапевтическое средство против диабета

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2092580T3 (es)	1990-11-30	1996-12-01	Teijin Ltd	Derivado de 2-ariltiazol y composicion farmaceutica que contiene el mismo.
WO2003013543A1 (en) *	2001-08-08	2003-02-20	Genomed, Llc	Treatment or prevention of acute renal failure
EP1940397A4 (en) *	2005-08-03	2010-01-20	Takeda Pharmaceuticals North A	METHOD FOR TREATING HYPERTONIA
EP3205337A1 (en) *	2005-08-18	2017-08-16	Teijin Pharma Limited	Formulation having accurate dose-dividing function
EP2101761A4 (en)	2006-11-13	2010-01-27	Takeda Pharmaceuticals North A	METHODS FOR PRESERVING RENAL FUNCTION USING XANTHINE OXYDOREDUCTASE INHIBITORS
CN101658505A (zh) *	2009-09-29	2010-03-03	北京华禧联合科技发展有限公司	非布索坦的缓释制剂及其制备方法
PE20170306A1 (es) *	2010-06-16	2017-05-06	Takeda Pharmaceuticals Usa Inc	Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa

2011
- 2011-06-24 WO PCT/JP2011/064569 patent/WO2011162390A1/ja not_active Ceased
- 2011-06-24 UY UY0001033468A patent/UY33468A/es not_active Application Discontinuation
- 2011-06-24 MX MX2012015040A patent/MX2012015040A/es not_active Application Discontinuation
- 2011-06-24 MY MYPI2012701137A patent/MY160963A/en unknown
- 2011-06-24 TW TW100122222A patent/TW201215389A/zh unknown
- 2011-06-24 EP EP11798271.0A patent/EP2586442A4/en not_active Withdrawn
- 2011-06-24 PH PH1/2012/502487A patent/PH12012502487A1/en unknown
- 2011-06-24 RU RU2013103366/15A patent/RU2013103366A/ru unknown
- 2011-06-24 US US13/806,370 patent/US20130109726A1/en not_active Abandoned
- 2011-06-24 JP JP2012521553A patent/JPWO2011162390A1/ja not_active Ceased
- 2011-06-24 AR ARP110102214A patent/AR082022A1/es unknown
- 2011-06-24 SG SG2012094645A patent/SG186798A1/en unknown
- 2011-06-24 UA UAA201300872A patent/UA107716C2/ru unknown
- 2011-06-24 BR BR112012032543A patent/BR112012032543A2/pt not_active IP Right Cessation
- 2011-06-24 CA CA2803163A patent/CA2803163A1/en not_active Abandoned
- 2011-06-24 KR KR1020127033036A patent/KR20130088755A/ko not_active Withdrawn
- 2011-06-24 MA MA35480A patent/MA34328B1/fr unknown
- 2011-06-24 CN CN2011800311202A patent/CN102958521A/zh active Pending
- 2011-06-24 AU AU2011270133A patent/AU2011270133B2/en not_active Ceased
- 2011-06-24 PE PE2012002449A patent/PE20130241A1/es not_active Application Discontinuation
- 2011-06-24 NZ NZ605516A patent/NZ605516A/en not_active IP Right Cessation
2012
- 2012-11-30 TN TNP2012000568A patent/TN2012000568A1/en unknown
- 2012-12-11 ZA ZA2012/09388A patent/ZA201209388B/en unknown
- 2012-12-20 CO CO12230952A patent/CO6660504A2/es unknown
- 2012-12-20 EC ECSP12012352 patent/ECSP12012352A/es unknown
- 2012-12-21 CL CL2012003661A patent/CL2012003661A1/es unknown

Also Published As

Publication number	Publication date
EP2586442A4 (en)	2014-01-01
TN2012000568A1 (en)	2014-04-01
MX2012015040A (es)	2013-02-07
ECSP12012352A (es)	2013-02-28
PE20130241A1 (es)	2013-03-04
WO2011162390A1 (ja)	2011-12-29
CO6660504A2 (es)	2013-04-30
AU2011270133A1 (en)	2013-01-10
CL2012003661A1 (es)	2013-04-01
US20130109726A1 (en)	2013-05-02
KR20130088755A (ko)	2013-08-08
CA2803163A1 (en)	2011-12-29
JPWO2011162390A1 (ja)	2013-08-22
NZ605516A (en)	2015-02-27
UY33468A (es)	2012-01-31
AU2011270133B2 (en)	2014-03-20
MA34328B1 (fr)	2013-06-01
RU2013103366A (ru)	2014-07-27
CN102958521A (zh)	2013-03-06
MY160963A (en)	2017-03-31
AR082022A1 (es)	2012-11-07
UA107716C2 (ru)	2015-02-10
BR112012032543A2 (pt)	2016-11-22
EP2586442A1 (en)	2013-05-01
ZA201209388B (en)	2013-08-28
SG186798A1 (en)	2013-02-28
PH12012502487A1 (en)	2017-08-09

Publication	Publication Date	Title
JP6508544B2 (ja)	2019-05-08	腫瘍を治療するための薬用組成物
JP2021529780A (ja)	2021-11-04	Ｎｌｒｐ３アンタゴニストを使用するｔｎｆ阻害剤に対して抵抗性の対象のための治療の方法又は治療を選択する方法
JP6464139B2 (ja)	2019-02-06	ブロモドメイン含有タンパク質の阻害のための方法および組成物
KR20160043118A (ko)	2016-04-20	가속화된 경화반 퇴행을 위한 조성물 및 치료방법
JP2013507415A5 (es)	2014-04-24
JP2017214387A (ja)	2017-12-07	増殖性疾患の治療のためのｈｓｐ９０阻害剤と組み合わせた２−カルボキサミドシクロアミノウレア誘導体
CN102300568A (zh)	2011-12-28	Hif-1蛋白积聚的抑制剂
JP2021522247A (ja)	2021-08-30	肝疾患における好中球エラスターゼ阻害薬の使用
JP2020189845A5 (es)	2021-04-01
TW200804603A (en)	2008-01-16	PDE inhibitors and combinations thereof for the treatment of urological disorders
JPWO2020095971A1 (ja)	2021-10-07	老化細胞を除去する方法、および老化細胞の調製方法
JP2023057082A (ja)	2023-04-20	ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
TW201215389A (en)	2012-04-16	Sustained-release therapeutic agent for hypertension and renal dysfunction
JP2022505033A (ja)	2022-01-14	ゲムカベン、薬学的に許容されるその塩、その組成物、およびその使用方法
FR2985185A1 (fr)	2013-07-05	Utilisation en therapeutique de derives d'imidazopyridine
HK1179890A (en)	2013-10-11	Sustained-release therapeutic agent for hypertension and renal dysfunction
CN114401745A (zh)	2022-04-26	包含fxr激动剂的治疗
KR20240007258A (ko)	2024-01-16	리실 옥시다제의 억제제로서 비티아졸 유도체
JP7540946B2 (ja)	2024-08-27	アシルチオウレア化合物とアビラテロンの併用療法
JPWO2004093858A1 (ja)	2006-07-13	Ｍｍｐ発現抑制剤
JP2025533120A (ja)	2025-10-03	イミダゾリジニルバニリン酸エーテル誘導体の線維化を伴う疾患の治療における使用
JP6243844B2 (ja)	2017-12-06	トロンビン受容体アンタゴニストを有効成分とする肺高血圧症の予防治療剤
AU2021358394A1 (en)	2023-04-13	Combination of encorafenib and binimetinib as adjuvant treatment for resected stage II melanoma
CN106536519A (zh)	2017-03-22	唑苯衍生物的晶体
HK40027589A (en)	2021-01-22	Gemcabene, pharmaceutically acceptable salts thereof, compositions thereof and methods of use therefor